AstraZeneca Pharma India Limited Financial Ratios
ASTRAZEN · Healthcare · Current price ₹5,932
P/E ratio
79.1x
P/B ratio
19.6x
ROE
21.5%
ROCE
26.1%
Debt / Equity
0.13
Dividend yield
0.5%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 79.1x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 19.6x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 21.5% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 26.1% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.13 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with AstraZeneca Pharma India Limited's latest numbers.
AstraZeneca Pharma India Limited profitability
AstraZeneca Pharma India Limited generates a return on equity of 21.5% and a return on capital employed of 26.1%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.13 and a P/E of 79.1x, AstraZeneca Pharma India Limited is conservatively financed. Our overall business-quality score for the company is 5.8 / 10.
Understand the ratios
More on AstraZeneca Pharma India Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.